Article Text

PDF
AB0233 Remission according to RAPID3 (routine assessment of patient index data 3) in patients with rheumatoid arthritis: a cross-sectional study from routine care at 3 usa sites
  1. I Castrejon1,
  2. MJ Bergman2,
  3. KA Gibson3,4,5,
  4. Y Yazici6,
  5. JA Block1,
  6. T Pincus1
  1. 1Rheumatology, Rush University Medical Center, Chicago
  2. 2Rheumatology, Taylor Hospital, Ridley Park, United States
  3. 3Rheumatology, Liverpool Hospital
  4. 4Ingham Research Institute, Liverpool
  5. 5University of NSW, Sydney, Australia
  6. 6Rheumatology, NYU Hospital for Joint Diseases, New York, United States

Abstract

Background RAPID3 remission criteria provide similar results to DAS28 criteria, although less stringent compared to ACR/EULAR Boolean criteria. RAPID3 remission criteria are more feasible in routine care1 and have been reported at 25% in patients from France1 and 21% from Norway2.

Objectives We examined the proportion of patients in remission and 3 other severity categories according to RAPID3 at 3 sites at which MDHAQ is completed by all patients in routine care.

Methods All patients seen at each rheumatology site complete an MDHAQ/RAPID3 at all visits in the waiting area as part of their routine care. The MDHAQ includes 0–10 scores for physical function, pain and patient global estimate, compiled into a 0–30 RAPID3, as well as scores for fatigue, RADAI self-report of painful joints, and demographic data. Physicians complete a global assessment (DOCGL) on a 0–10 visual analog scale (VAS). A random visit with complete questionnaire data for each RA patient from each site was included in the analyses. The proportion of patients in 4 RAPID3 categories, high severity (>12/30), moderate severity (6.1–12), low severity (3.1–6), and remission (≤3), was computed. MDHAQ demographic and clinical measures and DOCGL were compared in the 4 RAPID3 severity groups using chi-square and ANOVA tests.

Results 420 RA patients from the 3 sites were analyzed. Remission rates according to RAPID3 severity ranged from 23% to 26%, similar to reported rates from France and Norway. Low severity ranged from 7–24%, moderate severity from 23–29% and high severity from 21–46%. Age and sex were similar in the disease severity categories at the 3 sites (Table). Patients in the moderate and high severity groups at each site had higher scores for fatigue, RADAI self-reported joint pain, and DOCGL.

Table 1.

Mean (SD) for demographic and clinical characteristic of patients in remission versus other disease severity categories according to RAPID3 in each site. *p<0.001

Conclusions Similar RAPID3 remission rates were seen at 3 USA sites (about 24%), comparable to results from France and Norway.

References

  1. Castrejon I, Dougados M, et al. J Rheumatol 2013, 40(4):386–393.

  2. Uhlig T, Lie E, et al. J Rheumatol 2016, 43(4):716–723.

References

Disclosure of Interest I. Castrejon: None declared, M. Bergman: None declared, K. Gibson: None declared, Y. Yazici: None declared, J. Block: None declared, T. Pincus Shareholder of: Health Report Services, Inc

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.